Arrayit Corporation Blood Tests Diagnose Early Stage Cancers and Communicable Diseases

SUNNYVALE, CA, Nov 02 (MARKET WIRE) --
Arrayit Corporation (OTCBB: ARYC) is pleased to join the federal
government in their efforts to help control health care costs by
leveraging Arrayit's leading edge health care platform.

For more than 150 years, traditional medicine has relied on a 'standards
of care' model, which utilizes large cohorts of individuals as the data
set and essentially treats every person in an identical manner. While this
medical model provides a good paradigm for standard health care practices,
it is woefully deficient in that it fails to include genetic and
epigenetic differences between people as well as the interplay between
our genes and environmental factors including medication, diet and other
lifestyle considerations. In a major paradigm shift, personalized
medicine is gaining rapid popularity in that it endeavors to provide
customized health care to individuals inclusive of genetics, epigenetics
and the environment, leading to early stage diagnosis of diseases that
have exacted a heavy cost in quality and length of life and dollars spent
in late stage treatment.

Personalized medicine is a vastly superior advance in health care if it
can be delivered at a rate equivalent to or less than the current
standards of care model. As a next generation health care company,
Arrayit Corporation is capable of delivering personalized medical
information to the public at a fraction of current costs, owing to the
company's unique ability to miniaturize, automate and massively
parallelize genomic and proteomic tests. In simple terms, these molecular
diagnostic tests, requiring only a blood sample, will be more accurate
and less personally invasive than many traditional cancer screening
methods. Arrayit's patented microarray manufacturing technology and
Variation Identification Platform (VIP) procedures, deployed in clinical
laboratories and reference centers, are capable of testing entire
population groups. Arrayit personalized medical tests for pre-symptomatic
ovarian cancer detection, H1N1 screening, and Parkinson's Disease
diagnostics represent only a few of the collaborative milestones soon to
be announced.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and
empowers the genetic, research, pharmaceutical, and diagnostic communities
through the discovery, development and manufacture of proprietary life
science technologies and consumables for disease prevention, treatment and
cure. It now offers over 650 products to a customer base, including most
every major university, pharmaceutical and biotech company, major
agricultural and chemical company, government agency, national research
foundation and many private sector enterprises. Please visit
www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in
this release that constitute forward-looking statements are based on
currently available information, involve certain risks and uncertainties
and the Company assumes no responsibility to update any such
forward-looking statement. The following factors, among others, may cause
actual results to differ materially from the results suggested in the
forward-looking statements. Risks that may result from changes in the
Company's business operations; our ability to keep pace with
technological advances; significant competition in the biomedical
business; our relationships with key suppliers and customers; quality and
consumer acceptance of newly introduced products; market volatility;
non-availability of product; excess inventory; price and product
competition; new product introductions, the outcome of our legal
disputes; the possibility that the review of our prior filings by the SEC
may result in changes to our financial statements; and the possibility
that stockholders or regulatory authorities may initiate proceedings
against Arrayit and/or our officers and directors as a result of any
restatements. Risk factors associated with our business, including some
of the facts set forth herein, are detailed in the Company's Form 10-K/A
for the fiscal year ended December 31, 2008 and Form 10-Q/A for the
fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal
third quarter ended September 30, 2008.

Media contact:
Rod Mitchell
Tel: 281-350-5506
mediarod@aol.com

Copyright 2009, Market Wire, All rights reserved.

-0-